title: Splenic marginal zone lymphoma in 5 dogs (2001-2008).
abstract: BACKGROUND
  Splenic marginal zone lymphomas (MZL) in dogs arise from the marginal zone of B-cell follicles and can progress slowly.
  
  
  OBJECTIVE
  To describe clinical features, treatment, and outcome of dogs with splenic MZL.
  
  
  METHODS
  Five dogs with naturally occurring MZL.
  
  
  METHODS
  Clinical, laboratory, and follow-up data were retrospectively reviewed. Diagnosis was based on clinical, histopathological, and immunophenotypic features.
  
  
  RESULTS
  All dogs had stage IV disease; among them, 2 were symptomatic (substage "b") because of splenic rupture. Four dogs underwent splenectomy and adjuvant doxorubicin, and 1 dog underwent surgery only. Three out of the 4 dogs treated with surgery and chemotherapy died of causes unrelated to lymphoma, after 760, 939, and 1,825 days, whereas the remaining dog was alive and in complete remission after 445 days. The dog not receiving any adjuvant treatment had recurrence of the tumor after 180 days.
  
  
  CONCLUSIONS
  Splenic MZL appears indolent and can benefit from splenectomy, with or without systemic chemotherapy.
authors.affiliation: Department of Veterinary Clinical Sciences, School of Veterinary Medicine, University of Milan, Milan, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Stefanello
authors.forename: P
authors.initials: P
authors.lastname: Valenti
authors.forename: E
authors.initials: E
authors.lastname: Zini
authors.forename: S
authors.initials: S
authors.lastname: Comazzi
authors.forename: M E
authors.initials: ME
authors.lastname: Gelain
authors.forename: P
authors.initials: P
authors.lastname: Roccabianca
authors.forename: G
authors.initials: G
authors.lastname: Avallone
authors.forename: M
authors.initials: M
authors.lastname: Caniatti
authors.forename: L
authors.initials: L
authors.lastname: Marconato
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000737:chemistry / Q000235:genetics; D004283:Dog Diseases / Q000473:pathology* / Q000628:therapy; D004285:Dogs; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D007150:Immunohistochemistry / Q000662:veterinary; D018442:Lymphoma, B-Cell, Marginal Zone / Q000235:genetics / Q000473:pathology / Q000628:therapy / Q000662:veterinary*; D008297:Male; D016133:Polymerase Chain Reaction / Q000662:veterinary; D012189:Retrospective Studies; D013156:Splenectomy / Q000662:veterinary; D013160:Splenic Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy / Q000662:veterinary*; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D004273:DNA, Neoplasm; D004317:Doxorubicin